BBO-11818 drug page Clinical trials

Trials with BBO-11818

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

1Trials
1Recruiting
2Countries
665Planned patients

Showing 1–1 of 1

BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Recruiting Phase 1 665 patients NCT06917079

A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.

United States, Australia Mar 2025 – Sept 2029 Interventional

Where the recruiting trials are